{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:22:17Z","timestamp":1790738537280,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"am","delay-in-days":337,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Assistance Publique\u2013H\u00f4pitaux de Paris"},{"name":"Programme Hospitalier de Recherche Clinique\u2014PHRC"},{"DOI":"10.13039\/501100004690","name":"Minist\u00e8re de la Sant\u00e9","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004690","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Mundipharma"},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Mundipharma"},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007013","name":"Hoffman-la Roche","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"crossref"}]},{"name":"GSK"},{"name":"BMS"},{"DOI":"10.13039\/100006483","name":"Abbvie","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Association Oligocyte"},{"name":"Association pour le d\u00e9veloppement des neurosciences \u00e0 Avicenne"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.ejca.2018.12.025","type":"journal-article","created":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T12:09:05Z","timestamp":1549022945000},"page":"129-136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Angiotensin II receptor blockers, steroids and radiotherapy in glioblastoma\u2014a randomised multicentre trial (ASTER trial). An ANOCEF study"],"prefix":"10.1016","volume":"109","author":[{"given":"R.","family":"Ursu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Psimaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Chinot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Le Rhun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Ricard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Charissoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Cuzzubbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Sejalon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Quillien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Hoang-Xuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Ducray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-J.","family":"Portal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Tibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Mandonnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Levy-Piedbois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Vicaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.F.","family":"Carpentier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2018.12.025_bib1","doi-asserted-by":"crossref","first-page":"15017","DOI":"10.1038\/nrdp.2015.17","article-title":"Glioma","volume":"1","author":"Weller","year":"2015","journal-title":"Nat Rev Dis Prim"},{"issue":"10","key":"10.1016\/j.ejca.2018.12.025_bib2","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.ejca.2018.12.025_bib3","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1001\/jama.2015.16669","article-title":"Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial","volume":"314","author":"Stupp","year":"2015","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.ejca.2018.12.025_bib4","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3389\/fncel.2014.00418","article-title":"Gliomas and the vascular fragility of the blood brain barrier","volume":"8","author":"Dubois","year":"2014","journal-title":"Front Cell Neurosci"},{"issue":"1","key":"10.1016\/j.ejca.2018.12.025_bib5","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11060-010-0142-8","article-title":"Steroid requirements during radiotherapy for malignant gliomas","volume":"100","author":"Marantidou","year":"2010","journal-title":"J Neuro Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2018.12.025_bib6","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/nop\/npu029","article-title":"Corticosteroid use in neuro-oncology: an update","volume":"2","author":"Roth","year":"2015","journal-title":"Neuro Oncol Pract"},{"issue":"Pt 5","key":"10.1016\/j.ejca.2018.12.025_bib7","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/brain\/aww046","article-title":"Corticosteroids compromise survival in glioblastoma","volume":"139","author":"Pitter","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.ejca.2018.12.025_bib8","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nrclinonc.2009.14","article-title":"VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer","volume":"6","author":"Gerstner","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2018.12.025_bib9","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ejca.2018.12.025_bib10","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2012.43.9455","article-title":"Steroid-sparing effect of corticorelin acetate in peritumoral cerebral edema is associated with improvement in steroid-induced myopathy","volume":"31","author":"Recht","year":"2013","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.ejca.2018.12.025_bib11","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.1002\/cncr.25945","article-title":"Boswellia serrata acts on cerebral edema in patients irradiated for brain tumors: a prospective, randomized, placebo-controlled, double-blind pilot trial","volume":"117","author":"Kirste","year":"2011","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.ejca.2018.12.025_bib12","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1111\/j.1468-1331.2012.03766.x","article-title":"Steroid-sparing effects of angiotensin-II inhibitors in glioblastoma patients","volume":"19","author":"Carpentier","year":"2012","journal-title":"Eur J Neurol"},{"issue":"3","key":"10.1016\/j.ejca.2018.12.025_bib13","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s00415-015-8016-9","article-title":"Impact of Angiotensin-II receptor blockers on vasogenic edema in glioblastoma patients","volume":"263","author":"Kourilsky","year":"2016","journal-title":"J Neurol"},{"issue":"3","key":"10.1016\/j.ejca.2018.12.025_bib14","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/glia.10117","article-title":"Multiple angiotensin receptor subtypes in normal and tumor astrocytes in\u00a0vitro","volume":"39","author":"Fogarty","year":"2002","journal-title":"Glia"},{"issue":"5","key":"10.1016\/j.ejca.2018.12.025_bib15","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/sj.bjc.6601646","article-title":"Renin and angiotensinogen expression and functions in growth and apoptosis of human glioblastoma","volume":"90","author":"Juillerat-Jeanneret","year":"2004","journal-title":"Br J Canc"},{"key":"10.1016\/j.ejca.2018.12.025_bib16","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0006-291X(02)00496-5","article-title":"Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis","volume":"294","author":"Fujita","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.ejca.2018.12.025_bib17","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1172\/JCI16645","article-title":"Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth","volume":"112","author":"Egami","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ejca.2018.12.025_bib18","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1038\/sj.bjc.6602483","article-title":"Blockage of angiotensin II type I receptor decreases the synthesis of growth factors and induces apoptosis in C6 cultured cells and C6 rat glioma","volume":"92","author":"Arrieta","year":"2005","journal-title":"Br J Canc"},{"key":"10.1016\/j.ejca.2018.12.025_bib19","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1054\/bjoc.2001.2102","article-title":"AT1 receptor is present in glioma cells; its blockage reduces the growth of rat glioma","volume":"85","author":"Rivera","year":"2001","journal-title":"Br J Canc"},{"key":"10.1016\/j.ejca.2018.12.025_bib20","doi-asserted-by":"crossref","first-page":"4201","DOI":"10.1002\/cncr.27392","volume":"118","author":"Quillien","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2018.12.025_bib21","doi-asserted-by":"crossref","first-page":"61916","DOI":"10.18632\/oncotarget.11322","article-title":"Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial","volume":"7","author":"Quillien","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2018.12.025_bib22","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00401-009-0632-y","article-title":"Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis","volume":"119","author":"Camelo-Piragua","year":"2010","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.ejca.2018.12.025_bib23","first-page":"46","article-title":"Use of dexamethasone in treatment of cerebral edema associated with brain tumors","volume":"81","author":"Galicich","year":"1961","journal-title":"J Lancet"},{"issue":"5","key":"10.1016\/j.ejca.2018.12.025_bib24","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ccell.2014.10.006","article-title":"Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia","volume":"26","author":"Jain","year":"2014","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.ejca.2018.12.025_bib25","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1093\/carcin\/bgn171","article-title":"The renin-angiotensin system and malignancy","volume":"29","author":"Ager","year":"2008","journal-title":"Carcinogenesis"},{"issue":"11","key":"10.1016\/j.ejca.2018.12.025_bib26","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nrc2945","article-title":"The renin-angiotensin system and cancer: old dog, new tricks","volume":"10","author":"George","year":"2010","journal-title":"Nat Rev Canc"},{"key":"10.1016\/j.ejca.2018.12.025_bib27","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1038\/ncomms3516","article-title":"Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels","volume":"4","author":"Chauhan","year":"2013","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2018.12.025_bib28","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1038\/sj.bjc.6605955","article-title":"Inhibition of renin\u2013angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine","volume":"103","author":"Nakai","year":"2010","journal-title":"Br J Canc"},{"key":"10.1016\/j.ejca.2018.12.025_bib29","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s00432-009-0587-3","article-title":"Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy","volume":"135","author":"Wilop","year":"2009","journal-title":"J Canc Res Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2018.12.025_bib30","first-page":"189","article-title":"Effect of angiotensin system inhibitors on survival in patients receiving chemotherapy for advanced non-small-cell lung cancer","volume":"18","author":"Menter","year":"2017","journal-title":"Clin Lung Canc"},{"key":"10.1016\/j.ejca.2018.12.025_bib31","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/j.ejca.2011.04.019","article-title":"Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination","volume":"47","author":"Keizman","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2018.12.025_bib32","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/annonc\/mdv147","article-title":"Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma","volume":"26","author":"Izzedine","year":"2015","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2018.12.025_bib33","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/ene.12746","article-title":"Impact of renin-angiotensin system blockade on clinical outcome in glioblastoma","volume":"22","author":"Januel","year":"2015","journal-title":"Eur J Neurol"},{"issue":"2","key":"10.1016\/j.ejca.2018.12.025_bib34","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s11060-017-2528-3","article-title":"Effect of angiotensin system inhibitors on survival in newly diagnosed glioma patients and recurrent glioblastoma patients receiving chemotherapy and\/or bevacizumab","volume":"134","author":"Levin","year":"2017","journal-title":"J Neuro Oncol"},{"key":"10.1016\/j.ejca.2018.12.025_bib35","doi-asserted-by":"crossref","DOI":"10.1007\/s11060-018-2786-8","article-title":"Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma?","author":"Happold","year":"2018","journal-title":"J Neuro Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2018.12.025_bib36","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N Engl J Med"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804919300036?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804919300036?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:23:50Z","timestamp":1760732630000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804919300036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":36,"alternative-id":["S0959804919300036"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2018.12.025","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Angiotensin II receptor blockers, steroids and radiotherapy in glioblastoma\u2014a randomised multicentre trial (ASTER trial). An ANOCEF study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2018.12.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}